Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Empagliflozin + metformin + sitagliptin) by Chong Kun Dang Pharmaceutical for Type 2 Diabetes: Likelihood of Approval
(Empagliflozin + metformin + sitagliptin) is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for...